Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Primary Hyperoxaluria Type 1 With Nedosiran

NCT05993416 is registered in ClinicalTrials.gov with Dicerna Pharmaceuticals, Inc., a Novo Nordisk company as lead sponsor.

NCT NCT05993416
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05993416 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Primary Hyperoxaluria Type 1 With Nedosiran
Lead sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Phase
Expanded access
Overall status
No longer available
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

primary hyperoxaluria type 1 (ph1)